CTOs on the Move

Earlens

www.earlens.com

 
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens® Contact Hearing Solution, which directly vibrates the eardrum with a tiny lens in order to activate the natural hearing process. This revolutionary, nonsurgical hearing solution delivers the broadest bandwidth available today and superior sound quality. The Earlens® Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. We believe that people with hearing loss shouldn`t have to think about their hearing in everyday situations. Earlens was ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.earlens.com
  • 4045-A Campbell Avenue
    Menlo Park, CA USA 94025
  • Phone: 650.366.9000

Executives

Name Title Contact Details

Funding

Earlens raised $34M on 06/16/2016
Earlens raised $73M on 06/05/2017
Earlens raised $87M on 10/22/2018
Earlens raised $33.1M on 01/07/2021

Similar Companies

Telemed Systems Inc

Telemed Systems Inc is a Hudson, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blue Water Medical

Blue Water Medical is a Gulf Shores, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

www.biosig.com

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.

Medafor

Medafor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evofem Biosciences

Evofem, Inc. is a privately held biotechnology company that discovers, develops and commercializes prescription and over-the-counter products in the areas of feminine care, contraception, and the prevention of sexually transmitted infections. Evofem, Inc. is committed to delivering effective, woman-controlled, rapidly reversible forms of contraception to women globally. In February 2013, Evofem entered into a strategic alliance with Woman Care Global, a nonprofit organization whose mission is to provide access to quality, affordable, women`s healthcare products through a sustainable value chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, Woman Care Global provides sales, marketing and global distribution support to Evofem`s products.